Phase 2 study of pembrolizumab in patients with advanced rare cancers

• Published in: Journal for immunotherapy of cancer Vol. 8; no. 1; p. e000347
• Main Authors: Naing, Aung, Meric-Bernstam, Funda, Stephen, Bettzy, Karp, Daniel D, Hajjar, Joud, Rodon Ahnert, Jordi, Piha-Paul, Sarina A, Colen, Rivka R, Jimenez, Camilo, Raghav, Kanwal P, Ferrarotto, Renata, Tu, Shi-Ming, Campbell, Matthew, Wang, Linghua, Sabir, Sarjeel H, Tapia, Coya, Bernatchez, Chantale, Frumovitz, Michael, Tannir, Nizar, Ravi, Vinod, Khan, Saria, Painter, Jeane M, Abonofal, Abulrahman, Gong, Jing, Alshawa, Anas, McQuinn, Lacey M, Xu, Mingxuan, Ahmed, Sara, Subbiah, Vivek, Hong, David S, Pant, Shubham, Yap, Timothy A, Tsimberidou, Apostolia M, Dumbrava, Ecaterina E Ileana, Janku, Filip, Fu, Siqing, Simon, Richard M, Hess, Kenneth R, Varadhachary, Gauri R, Amir Habra, Mouhammed
• Format: Journal Article
• Language: English
• Published: England BMJ Publishing Group Ltd 01.03.2020; BMJ Publishing Group LTD; BMJ Publishing Group
• Subjects: Apoptosis; Cancer; Clinical/Translational Cancer Immunotherapy; Disease; Drug dosages; FDA approval; Immunotherapy; Ligands; Medical prognosis; Monoclonal antibodies; Neuroendocrine tumors; oncology; Sarcoma; Squamous cell carcinoma; Targeted cancer therapy; Testicular cancer; Thyroid cancer; Tumors; tumours; United States > US; tumours; oncology

BackgroundPatients with advanced rare cancers have poor prognosis and few treatment options. As immunotherapy is effective across multiple cancer types, we aimed to assess pembrolizumab (programmed cell death 1 (PD-1) inhibitor) in patients with advanced rare cancers.MethodsIn this open-label, phase...